Evaluation of 24 protocols for the production of platelet-rich fibrin
Richard J Miron, Jihua Chai, Masako Fujioka-Kobayashi, Anton Sculean, Yufeng Zhang, Richard J Miron, Jihua Chai, Masako Fujioka-Kobayashi, Anton Sculean, Yufeng Zhang
Abstract
Background: The aim of this study was to evaluate 24 protocols for the production of platelet rich fibrin (PRF) produced via horizontal centrifugation to better understand cell separation following protocols at various times and speeds.
Methods: All protocols were compared utilizing a recent method to quantify cells in PRF in 1 mL sequential layers pipetted from the upper layer downwards until all 10 mL were harvested. In total, 960 complete blood counts (CBCs) were investigated. Both solid and liquid-based PRF protocols were investigated following 24 protocols involving 6 relative centrifugal force (RCF) values (100, 200, 400, 700, 1000 and 1200g) at 4 centrifugation times (3, 5, 8 and 12 min).
Results: In general, platelets could more easily accumulate in the upper 4 layers when compared to leukocytes owing to their lower cellular density. Protocol time seemed to have a greater impact on the final cell layer separation when compared to the effect of speed. Protocols of greater than 8 min at 400g led to no leukocyte accumulation in the upper PRF layers (found specifically within the buffy coat). Protocols at or below 200g were unable to effectively accumulate platelets/leukocytes. The optimal centrifugation speed and time for solid-PRF ranged between 400 and 700g for 8 min. It was noted that variability in patient baseline platelet/leukocyte/erythrocyte counts (hematocrit) significantly affected cell layer separation. This finding was more pronounced at lower centrifugation speeds.
Conclusions: Within the investigated ranges, a protocol of 700g for 8 min presented the highest yield of platelets/leukocytes evenly distributed throughout the upper PRF layers.
Keywords: A-PRF; Advanced platelet-rich fibrin; L-PRF; Leukocyte and platelet-rich fibrin; i-PRF.
Conflict of interest statement
AS is an editorial board member for BMC Oral Health. RJM holds intellectual property for the production of PRF. All other authors declare that they have no competing interests.
Figures
References
- Miron RJ, Zucchelli G, Pikos MA, Salama M, Lee S, Guillemette V, Fujioka-Kobayashi M, Bishara M, Zhang Y, Wang HL, et al. Use of platelet-rich fibrin in regenerative dentistry: a systematic review. Clin Oral Invest. 2017;21(6):1913–1927. doi: 10.1007/s00784-017-2133-z.
- Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62(4):489–496. doi: 10.1016/j.joms.2003.12.003.
- Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85(6):638–646. doi: 10.1016/S1079-2104(98)90029-4.
- Cai YZ, Zhang C, Lin XJ. Efficacy of platelet-rich plasma in arthroscopic repair of full-thickness rotator cuff tears: a meta-analysis. J Shoulder Elbow Surg Am Shoulder Elbow Surg [et al] 2015;24(12):1852–1859. doi: 10.1016/j.jse.2015.07.035.
- Meheux CJ, McCulloch PC, Lintner DM, Varner KE, Harris JD. Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. Arthroscopy. 2016;32(3):495–505. doi: 10.1016/j.arthro.2015.08.005.
- Singh B, Goldberg LJ. Autologous platelet-rich plasma for the treatment of pattern hair loss. Am J Clin Dermatol. 2016;17:359–367. doi: 10.1007/s40257-016-0196-2.
- Anfossi G, Trovati M, Mularoni E, Massucco P, Calcamuggi G, Emanuelli G. Influence of propranolol on platelet aggregation and thromboxane B2 production from platelet-rich plasma and whole blood. Prostaglandins Leukot Essent Fatty Acids. 1989;36(1):1–7. doi: 10.1016/0952-3278(89)90154-3.
- Fijnheer R, Pietersz RN, de Korte D, Gouwerok CW, Dekker WJ, Reesink HW, Roos D. Platelet activation during preparation of platelet concentrates: a comparison of the platelet-rich plasma and the buffy coat methods. Transfusion. 1990;30(7):634–638. doi: 10.1046/j.1537-2995.1990.30790385523.x.
- Chow TW, McIntire LV, Peterson DM. Importance of plasma fibronectin in determining PFP and PRP clot mechanical properties. Thromb Res. 1983;29(2):243–248. doi: 10.1016/0049-3848(83)90146-9.
- Delaini F, Poggi A, Donati MB. Enhanced affinity for arachidonic acid in platelet-rich plasma from rats with Adriamycin-induced nephrotic syndrome. Thromb Haemost. 1982;48(3):260–262. doi: 10.1055/s-0038-1657275.
- Miron RJ, Zucchelli G, Pikos MA, Salama M, Lee S, Guillemette V, Fujioka-Kobayashi M, Bishara M, Zhang Y, Wang H-L, Coi J. Use of platelet-rich fibrin in regenerative dentistry: a systematic review. Clin Oral Invest. 2017;21(6):1913–1927. doi: 10.1007/s00784-017-2133-z.
- Miron RJ, Choukroun J, Ghanaati S. Necessity for standardization of relative centrifugal force values in studies on platelet rich fibrin; response to letter to the editor. J Periodontol. 2018;90:122–125.
- Ehrenfest DMD, Rasmusson L, Albrektsson TJ. Tib: classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF) Trends Biotechnol. 2009;27(3):158–167. doi: 10.1016/j.tibtech.2008.11.009.
- Kobayashi E, Fluckiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, Miron RJ. Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Invest. 2016;20(9):2353–2360. doi: 10.1007/s00784-016-1719-1.
- Miron RJ, Fujioka-Kobayashi M, Hernandez M, Kandalam U, Zhang Y, Ghanaati S, Choukroun J. Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry? Clin Oral Invest. 2017;21:2619–2627. doi: 10.1007/s00784-017-2063-9.
- Miron RJ, Chai J, Zheng S, Feng M, Sculean A, Zhang Y. A novel method for evaluating and quantifying cell types in platelet rich fibrin and an introduction to horizontal centrifugation. J Biomed Mater Res, Part A. 2019;107(10):2257–2271. doi: 10.1002/jbm.a.36734.
- Nunes CR, Roedersheimer M, Simske S, Luttges M. Effect of microgravity, temperature, and concentration on fibrin and collagen assembly. Microgravity Sci Technol. 1995;8(2):125–130.
- Ghanaati S, Booms P, Orlowska A, Kubesch A, Lorenz J, Rutkowski J, Landes C, Sader R, Kirkpatrick C, Choukroun J. Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. J Oral Implantol. 2014;40(6):679–689. doi: 10.1563/aaid-joi-D-14-00138.
- Takahashi A, Tsujino T, Yamaguchi S, Isobe K, Watanabe T, Kitamura Y, Okuda K, Nakata K, Kawase T: Distribution of platelets, transforming growth factor-beta1, platelet-derived growth factor-BB, vascular endothelial growth factor and matrix metalloprotease-9 in advanced platelet-rich fibrin and concentrated growth factor matrices. J Investig Clin Dent 2019:e12458.
- Miron RJ, Dham A, Dham U, Zhang Y, Pikos MA, Sculean A. The effect of age, gender, and time between blood draw and start of centrifugation on the size outcomes of platelet-rich fibrin (PRF) membranes. Clin Oral Invest. 2018;23:2179–2185. doi: 10.1007/s00784-018-2673-x.
- Varela HA, Souza JCM, Nascimento RM, Araujo RF, Jr, Vasconcelos RC, Cavalcante RS, Guedes PM, Araujo AA. Injectable platelet rich fibrin: cell content, morphological, and protein characterization. Clin Oral Invest. 2019;23(3):1309–1318. doi: 10.1007/s00784-018-2555-2.
Source: PubMed